Sivia Capital Partners LLC Grows Holdings in Bristol-Myers Squibb (NYSE:BMY)

Sivia Capital Partners LLC boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 10.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 4,292 shares of the biopharmaceutical company’s stock after purchasing an additional 410 shares during the quarter. Sivia Capital Partners LLC’s holdings in Bristol-Myers Squibb were worth $243,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Thoroughbred Financial Services LLC lifted its stake in Bristol-Myers Squibb by 9.5% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 10,353 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 901 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Bristol-Myers Squibb by 1.6% in the second quarter. Envestnet Asset Management Inc. now owns 2,268,887 shares of the biopharmaceutical company’s stock valued at $94,227,000 after buying an additional 34,643 shares in the last quarter. Retirement Planning Co of New England Inc. boosted its stake in shares of Bristol-Myers Squibb by 4.1% in the second quarter. Retirement Planning Co of New England Inc. now owns 10,634 shares of the biopharmaceutical company’s stock valued at $442,000 after purchasing an additional 418 shares during the period. Providence Wealth Advisors LLC increased its position in shares of Bristol-Myers Squibb by 1.9% during the second quarter. Providence Wealth Advisors LLC now owns 30,054 shares of the biopharmaceutical company’s stock worth $1,260,000 after acquiring an additional 552 shares during the period. Finally, Plato Investment Management Ltd raised its position in Bristol-Myers Squibb by 25.4% in the 2nd quarter. Plato Investment Management Ltd now owns 103,954 shares of the biopharmaceutical company’s stock valued at $4,317,000 after purchasing an additional 21,041 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,830 shares of Bristol-Myers Squibb stock in a transaction dated Friday, November 1st. The stock was purchased at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on BMY. Bank of America reissued a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Truist Financial increased their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets increased their target price on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a report on Tuesday, November 12th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Finally, Morgan Stanley increased their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $56.27.

Bristol-Myers Squibb Trading Down 1.1 %

BMY traded down $0.60 during mid-day trading on Monday, reaching $55.23. The stock had a trading volume of 4,675,553 shares, compared to its average volume of 9,287,350. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The stock has a market capitalization of $112.02 billion, a P/E ratio of -15.38, a P/E/G ratio of 15.20 and a beta of 0.45. The firm’s fifty day simple moving average is $57.44 and its two-hundred day simple moving average is $51.56.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the business posted $2.00 EPS. On average, equities analysts predict that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be given a dividend of $0.62 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.49%. The ex-dividend date of this dividend is Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is currently -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.